This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Epidemiology

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Approximately 4-7 million individuals are affected in the world and account for 7% to 15% of patients on renal replacement therapy (1)

It accounts for about 10% of people on dialysis. Annual incidence rates of end-stage kidney disease (ESKD) caused by ADPKD are between 6-8 per million per year in Europe (2)

Females are more likely to be diagnosed during early adulthood than males, possibly due to the use of abdominal ultrasound during pregnancy (3)

 

Reference:

  1. Mahboob M et al. Autosomal Dominant Polycystic Kidney Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
  2. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007 Apr 14;369(9569):1287-301.
  3. Willey C, Kamat S, Stellhorn R, et al. Analysis of nationwide data to determine the incidence and diagnosed prevalence of autosomal dominant polycystic kidney disease in the USA: 2013-2015. Kidney Dis (Basel). 2019 Mar;5(2):107-17.

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.